Blueprint Medicines Corp (NAS:BPMC)
$ 102.81 0.42 (0.41%) Market Cap: 6.44 Bil Enterprise Value: 6.09 Bil PE Ratio: 0 PB Ratio: 20.73 GF Score: 72/100

Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2020 / 12:50PM GMT
Release Date Price: $74.17 (+0.98%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning, everyone. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and with us this morning, we have Blueprint Medicines and Jeff Albers, CEO of the company.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

So Jeff, to start here, AYVAKIT, your first commercial drug, was approved in December in a genetically driven subset of patients with gastrointestinal stromal tumors. Just to remind everyone, can you just start by outlining the opportunity here for this indication?

Jeffrey W. Albers
Blueprint Medicines Corporation - CEO, President & Director

Sure. Thanks, Salveen. And on behalf of all the employees of Blueprint Medicines, thanks for including us in this virtual Goldman conference. And as always, we'll be making forward-looking statements, so we'd refer folks to our website or to the SEC documents for more detailed information.

So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot